Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA4 | P22748 | 2/20 | 0.68 |
| ▸ | CA6 | P23280 | 2/20 | 0.68 |
| ▸ | CA7 | P43166 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366012 | 0.92 | ALDH1A1 (0.63) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365099 | 0.92 | ALDH1A1 (0.65) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365095 | 0.92 | ALDH1A1 (0.65) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3366008 | 0.92 | ALDH1A1 (0.63) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365102 | 0.92 | ALDH1A1 (0.65) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3366005 | 0.87 | NPC1 (0.77) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365348 | 0.87 | NPC1 (0.77) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365355 | 0.87 | NPC1 (0.77) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL3365627 | 0.87 | ALDH1A1 (0.70) | ALDH1A1CA1CA2CA4CA6 | |
| SCHEMBL19793283 | 0.87 | MAPK1 (0.70) | ALDH1A1CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073544-B | PARP inhibitor pyrazolo-quinine derivative and synthesis method thereof | 上海应用技术大学 | 2024-07-23 | — | — | CN | disclosed |
| CN-117756793-A | 1,2, 4-heterodiazole derivatives and use thereof | 四川大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-115073544-A | PARP inhibitor pyrazoloquinine derivative and synthesis method thereof | 上海应用技术大学 | 2022-09-20 | — | — | CN | disclosed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2212284-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334317-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. | 2011-07-21 | — | — | US | disclosed |
| EP-2212284-A2 | CALCIUM RECEPTOR MODULATING AGENTS | Amgen Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051718-A2 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051718-A2 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1000620-B1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178133-A1 | CALCIUM RECEPTOR MODULATING AGENTS | CASR, CALCR, RYR1 | ALDH1A1 3977/4885CA1 719/4885CA2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.